P101: Combination of immune checkpoint inhibitors with BeGEV in the treatment of patients with relapsed and refractory classical Hodgkin’s lymphoma.

Detalles Bibliográficos
Autores principales: Mangasarova, Ya.K., Moiseeva, T.N., Al-Radi, L.S., Margolin, O.V., Gorenkova, L.G., Nesterova, E.S., Bagova, M.O., Fastova, E.A., Abdurashidova, R.R., Sarakaeva, Z.T., Dorokhina, Elena, Kravchenko, S.K., Magomedova, A.U., Zvonkov, E.E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Relapsed/Refractory
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621492/
http://dx.doi.org/10.1097/01.HS9.0000890972.83229.41

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621492/
http://dx.doi.org/10.1097/01.HS9.0000890972.83229.41

Ejemplares similares